KR890007720A - 조절 방출성 용량 형태 - Google Patents
조절 방출성 용량 형태 Download PDFInfo
- Publication number
- KR890007720A KR890007720A KR1019880014528A KR880014528A KR890007720A KR 890007720 A KR890007720 A KR 890007720A KR 1019880014528 A KR1019880014528 A KR 1019880014528A KR 880014528 A KR880014528 A KR 880014528A KR 890007720 A KR890007720 A KR 890007720A
- Authority
- KR
- South Korea
- Prior art keywords
- dosage form
- controlled release
- release dosage
- ethylcellulose
- drug
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title claims 13
- 238000013270 controlled release Methods 0.000 title claims 12
- 239000008187 granular material Substances 0.000 claims description 4
- 239000011247 coating layer Substances 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 10
- 239000001856 Ethyl cellulose Substances 0.000 claims 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 9
- 235000019325 ethyl cellulose Nutrition 0.000 claims 9
- 229920001249 ethyl cellulose Polymers 0.000 claims 9
- 230000002209 hydrophobic effect Effects 0.000 claims 8
- 239000000463 material Substances 0.000 claims 8
- 239000011248 coating agent Substances 0.000 claims 6
- 238000000576 coating method Methods 0.000 claims 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical class [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 239000000454 talc Substances 0.000 claims 4
- 229910052623 talc Inorganic materials 0.000 claims 4
- 235000012222 talc Nutrition 0.000 claims 4
- 239000002195 soluble material Substances 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical class O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 2
- 235000013539 calcium stearate Nutrition 0.000 claims 2
- 239000008116 calcium stearate Substances 0.000 claims 2
- 239000008119 colloidal silica Chemical class 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229940088417 precipitated calcium carbonate Drugs 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000011787 zinc oxide Chemical class 0.000 claims 2
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- -1 alkaline earth metal salts Chemical class 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000010410 layer Substances 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1,2 및 3도는 실시예 4 각각의 과립(또는 캡슐)의 시간에 대한 용해 백분율의 그래프를 나타낸다.
Claims (15)
- 필수적으로 약물을 함유하는 핵심부; 에틸셀룰로우즈 및 소수성 물질로 구성된 내부 피복층; 및 약물을 함유하는 외부 피복층으로 이루어진 조절 방출성 약학적 용량 형태.
- 제1항에 있어서, 에틸셀룰로우즈 단독, 또는 에틸셀룰로우즈와 수용성 물질의 혼합물로 구성된 중간 피복층을 내부피복층과 외부 피복층 사이에 추가로 형성시킨 조절 방출성 용량 형태.
- 제1 또는 2항에 있어서, 내부 피복층 중의 소수성 물질에 대한 에틸셀룰로우즈의 정량 비율이 1:1 내지 1:15(중량비)의 범위 이내인 조절 방출성 용량 형태.
- 제3항에 있어서, 외부 피복층에 이입된 약물에 대한 핵심부 중에 이입된 약물의 정량 비율이 1:1내지 20:1(중량비)의 범위 이내인 조절 방출성 용량 형태.
- 제4항에 있어서, 약물-함유 핵심부의 입자 크기가 직경 300㎛ 내지 2000㎛의 범위이고, 내부 피복층의 피복 비율[(에틸셀룰로우즈+소수성 물질의 중량/약물-함유 핵심부의 중량)×100]이고 5~50%의 범위이며, 중간 피복층에 사용된 에틸셀룰로우즈 양이 내부 피복층-피복된 핵심부의 양의 0.1 내지 10%의 범위인 조절 방출성 용량 형태.
- 제5항에 있어서, 상기 용량 형태가 직경 500㎛ 내지 2500㎛의 입자 크기를 갖는 과립인 조절 방출성 용량 형태.
- 제6항에 있어서, 소수성 물질이 탈크, 스테아르산 알칼리 토금속염, 산화 티탄, 침전된 탄산칼슘, 산화 아연 및 콜로이드성 실리카로 구성된 그룹으로부터 선택된 조절 방출성 용량 형태.
- 제7항에 있어서, 수용성 물질이 슈크로오즈, 락토오즈, 마크로골, 만니톨 및 솔비톨로 구성된 그룹으로부터 선택된 조절 방출성 용량 형태.
- 제8항에 있어서, 소수성 물질이 탈크, 스테아르산 마그네슘, 스테아르산 칼슘, 산화 티탄, 침전된 탄산칼슘, 산화 아연 또는 콜로이드성 실리카인 조절 방출성 용량 형태.
- 제9항에 있어서, 소수성 물질이 탈크, 스테아르산 마그네슘, 또는 스테아르산 칼슘인 조절 방출성 용량 형태.
- 제10항에 있어서, 소수성 물질이 탈크인 조절 방출성 용량 형태.
- 제11항에 있어서, 약물이 칼슘 길항제인 조절 방출성 용량 형태.
- 제12항에 있어서, 약물이 딜티아젬 히드로클로라이드인 조절 방출성 용량 형태.
- (1)약물-함유 핵심부를 에틸셀룰로우즈와 소수성 물질로 구성된 내부 피복층으로 피복하고, (2)단계 (1)의 생성물을 약물을 함유하는 외부 피복층으로 피복하는 단계로 구성된 조절 방출성 용량 형태의 조제 방법.
- 제14항에 있어서, 단계 (1)의 과립을 외부 피복층으로 피복하기 전에, 에틸셀룰로우즈 단독, 또는 에틸셀룰로우즈와 수용성 물질의 혼합물로 구성된 중간 피복층으로 피복하는 단계를 추가로 포함하는 제조 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP281189/1987 | 1987-11-06 | ||
JP28118987 | 1987-11-06 | ||
JP62-281189 | 1987-11-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR890007720A true KR890007720A (ko) | 1989-07-05 |
KR940002655B1 KR940002655B1 (ko) | 1994-03-28 |
Family
ID=17635585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019880014528A KR940002655B1 (ko) | 1987-11-06 | 1988-11-05 | 조절 방출성 용량 형태 |
Country Status (24)
Country | Link |
---|---|
US (1) | US4963365A (ko) |
EP (1) | EP0315414B1 (ko) |
KR (1) | KR940002655B1 (ko) |
CN (1) | CN1035099C (ko) |
AT (1) | ATE68343T1 (ko) |
AU (1) | AU610275B2 (ko) |
BG (1) | BG60638B1 (ko) |
CA (1) | CA1331565C (ko) |
DE (1) | DE3865631D1 (ko) |
DK (1) | DK175249B1 (ko) |
ES (1) | ES2027013T3 (ko) |
FI (1) | FI96273C (ko) |
FR (1) | FR2622799B1 (ko) |
GR (1) | GR3002915T3 (ko) |
HK (1) | HK44593A (ko) |
HU (1) | HU201468B (ko) |
IE (1) | IE60785B1 (ko) |
IL (1) | IL88083A (ko) |
NO (1) | NO176233C (ko) |
PH (1) | PH25905A (ko) |
PT (1) | PT88945B (ko) |
RU (1) | RU1816213C (ko) |
SG (1) | SG15493G (ko) |
ZA (1) | ZA888147B (ko) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169642A (en) * | 1988-06-24 | 1992-12-08 | Abbott Laboratories | Sustained-release drug dosage units |
US5268182A (en) * | 1988-06-24 | 1993-12-07 | Abbott Laboratories | Sustained-release drug dosage units of terazosin |
ES2044246T3 (es) * | 1989-02-11 | 1994-01-01 | Bayer Ag | Medicamentos con liberacion controlada del producto activo. |
US5258186A (en) * | 1989-03-10 | 1993-11-02 | Yamanouchi Pharmaceutical Co., Ltd. | Drug release controlling coating material for long acting formulations |
WO1990011074A1 (en) * | 1989-03-22 | 1990-10-04 | Pang Peter K T | Parathyroid hypertensive factor |
US5886012A (en) * | 1989-03-22 | 1999-03-23 | Peter K. T. Pang | Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5122384A (en) * | 1989-05-05 | 1992-06-16 | Kv Pharmaceutical Company | Oral once-per-day organic nitrate formulation which does not induce tolerance |
JP2558396B2 (ja) * | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
DK0585355T3 (da) * | 1991-05-20 | 1995-06-06 | Tanabe Seiyaku Co | Flerlagspræparat med reguleret frigivelse |
ZA923474B (en) * | 1991-05-20 | 1993-01-27 | Marion Merrell Dow Inc | Diltiazem formulation |
US5286497A (en) * | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
US5252337A (en) * | 1991-06-25 | 1993-10-12 | Eurand America, Inc. | Controlled release calcium channel blocker microcapsules |
GB9117361D0 (en) * | 1991-08-12 | 1991-09-25 | Euro Celtique Sa | Oral dosage form |
KR100221695B1 (ko) * | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
US5492700A (en) * | 1991-11-26 | 1996-02-20 | Warner-Lambert Company | Process and composition for the development of controlled release gemfibrozil dosage form |
DE69327745T2 (de) * | 1992-05-29 | 2000-09-21 | Nikken Chemicals Co., Ltd. | Tablette zur langsamen Freisetzung von Natriumvalproat |
DE4342091A1 (de) * | 1993-12-09 | 1995-06-14 | Asta Medica Ag | Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten |
US5447729A (en) * | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
US5830503A (en) * | 1996-06-21 | 1998-11-03 | Andrx Pharmaceuticals, Inc. | Enteric coated diltiazem once-a-day formulation |
TW477708B (en) * | 1996-09-13 | 2002-03-01 | Shionogi & Amp Co | Use of the thermal change to produce a substained release preparations and a process for their production |
US6524620B2 (en) | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
KR100396171B1 (ko) * | 1998-08-10 | 2003-08-27 | 아사히 가세이 가부시키가이샤 | 염산 파수딜의 경구 서방성 제제 |
US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
US6635277B2 (en) | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
US6946146B2 (en) | 2001-04-18 | 2005-09-20 | Nostrum Pharmaceuticals Inc. | Coating for a sustained release pharmaceutical composition |
US20040029959A1 (en) * | 2002-08-08 | 2004-02-12 | John Devane | Isosorbide mononitrate compositions and methods of their use |
US9107804B2 (en) | 2002-12-10 | 2015-08-18 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
CA2529984C (en) | 2003-06-26 | 2012-09-25 | Isa Odidi | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors |
CN1296046C (zh) * | 2003-12-23 | 2007-01-24 | 广州市医药工业研究所 | 盐酸地尔硫䓬控释胶囊剂及其制备方法 |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
WO2007092717A1 (en) * | 2006-02-07 | 2007-08-16 | Fmc Corporation | Latex or pseudolatex compositions coatings and coating processes |
EP2007360B1 (en) | 2006-04-03 | 2014-11-26 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
US8927010B2 (en) * | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8916588B2 (en) * | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) * | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
EP2529731A1 (en) * | 2011-06-01 | 2012-12-05 | Nitto Denko Corporation | Particulate preparation and method for producing the same |
FR2996418B1 (fr) * | 2012-10-09 | 2015-05-29 | Seppic Sa | Compositions alimentaires comprenant des capsules obtenues par coacervation ne mettant pas en œuvre de reticulant toxique |
WO2014078435A1 (en) | 2012-11-14 | 2014-05-22 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1172087A (fr) * | 1956-01-25 | 1959-02-05 | Bellon Labor Sa Roger | Perfectionnements concernant l'enrobage de préparations à effet retardé et à effet soutenu |
US2921883A (en) * | 1957-05-03 | 1960-01-19 | Smith Kline French Lab | Novel coating material for medicaments |
US2928770A (en) * | 1958-11-28 | 1960-03-15 | Frank M Bardani | Sustained action pill |
US3492397A (en) * | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
IT1153487B (it) * | 1982-04-15 | 1987-01-14 | Prophin Lab Spa | Prodotti farmaceutici in forma-ritardo e procedimento per ottenerli |
US4390406A (en) * | 1982-07-23 | 1983-06-28 | Allied Corporation | Replaceable outer junction double junction reference electrode |
JPS604120A (ja) * | 1983-06-22 | 1985-01-10 | Shionogi & Co Ltd | 作用持続型ピナシジル製剤 |
IE56999B1 (en) * | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
SE457505B (sv) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
DE3403329A1 (de) * | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe |
IT1206166B (it) * | 1984-07-26 | 1989-04-14 | Sigma Tau Ind Farmaceuti | Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione |
US4851228A (en) * | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
US4600645A (en) * | 1985-01-31 | 1986-07-15 | Warner-Lambert Company | Process for treating dosage forms |
JPS62103012A (ja) * | 1985-10-23 | 1987-05-13 | Eisai Co Ltd | 多重顆粒 |
US4842867A (en) * | 1986-05-09 | 1989-06-27 | Alza Corporation | Pulsed drug delivery of doxylamine |
US4795644A (en) * | 1987-08-03 | 1989-01-03 | Merck & Co., Inc. | Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins |
-
1988
- 1988-10-19 IL IL88083A patent/IL88083A/xx not_active IP Right Cessation
- 1988-10-26 IE IE324688A patent/IE60785B1/en not_active IP Right Cessation
- 1988-10-31 ZA ZA888147A patent/ZA888147B/xx unknown
- 1988-11-01 DE DE8888310271T patent/DE3865631D1/de not_active Expired - Lifetime
- 1988-11-01 ES ES198888310271T patent/ES2027013T3/es not_active Expired - Lifetime
- 1988-11-01 AT AT88310271T patent/ATE68343T1/de not_active IP Right Cessation
- 1988-11-01 EP EP88310271A patent/EP0315414B1/en not_active Expired - Lifetime
- 1988-11-03 CA CA000582132A patent/CA1331565C/en not_active Expired - Lifetime
- 1988-11-03 BG BG85941A patent/BG60638B1/bg unknown
- 1988-11-04 FR FR888814466A patent/FR2622799B1/fr not_active Expired - Lifetime
- 1988-11-04 HU HU885710A patent/HU201468B/hu unknown
- 1988-11-04 RU SU884356826A patent/RU1816213C/ru active
- 1988-11-04 DK DK198806180A patent/DK175249B1/da not_active IP Right Cessation
- 1988-11-04 NO NO884947A patent/NO176233C/no not_active IP Right Cessation
- 1988-11-04 FI FI885101A patent/FI96273C/fi not_active IP Right Cessation
- 1988-11-04 AU AU24727/88A patent/AU610275B2/en not_active Expired
- 1988-11-04 PT PT88945A patent/PT88945B/pt not_active IP Right Cessation
- 1988-11-04 US US07/267,085 patent/US4963365A/en not_active Expired - Lifetime
- 1988-11-04 PH PH3772A patent/PH25905A/en unknown
- 1988-11-05 CN CN88107687A patent/CN1035099C/zh not_active Expired - Lifetime
- 1988-11-05 KR KR1019880014528A patent/KR940002655B1/ko not_active IP Right Cessation
-
1991
- 1991-10-17 GR GR91401439T patent/GR3002915T3/el unknown
-
1993
- 1993-02-11 SG SG154/93A patent/SG15493G/en unknown
- 1993-05-06 HK HK445/93A patent/HK44593A/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR890007720A (ko) | 조절 방출성 용량 형태 | |
AU733801B2 (en) | Multiple unit effervescent dosage form | |
US5472708A (en) | Pulsatile particles drug delivery system | |
CA1139662A (en) | Simethicone antacid tablet | |
CA2081709A1 (en) | Controlled release pharmaceutical compositions | |
KR910004180A (ko) | 저작성 약제학적 정제를 제조하기 위한 회전과립화 공정 및 맛을 은폐하기 위한 피복공정 | |
KR930003905A (ko) | 약학적 결합 제제 | |
EP1736144A3 (en) | Orally disintegrable tablets | |
CA2137017A1 (en) | Controlled release pharmaceutical tablet having lenticular form | |
EP0327295A3 (en) | Tetracycline dosage form | |
AU610112B2 (en) | Tablet for pharmaceutical use able to release active substances at successive times | |
BR9904039A (pt) | Preparação de partìculas farmaceuticamente ativas | |
DE3773468D1 (de) | Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung. | |
ATE107857T1 (de) | Zusammensetzung mit kontrollierter freisetzung von dihydrocodein. | |
CA2221356A1 (en) | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids | |
DE60036874D1 (de) | Pellet formulierung mit gesteuerter freisetzung | |
AR019933A1 (es) | Granulos que tienen un nucleo recubierto con un agente antifungico y un polimero, un procedimiento para su preparacion, una forma de dosificacionfarmaceutica | |
BR9807368A (pt) | Comprimidos de oxacarvazepina revestidos com pelìcula | |
CA2121038A1 (en) | Oral preparation for release in lower digestive tracts | |
JPS61118317A (ja) | 圧縮コーテイングした分散し得る錠剤 | |
ATE169818T1 (de) | Carbamazepin-arzneiform mit verzögerter wirkstofffreisetzung | |
GR3003988T3 (ko) | ||
CN1130869A (zh) | 软壳明胶包囊的颗粒 | |
KR900017584A (ko) | 경구용 진해 조성물 | |
Benson et al. | Optimisation of Drug Delivery 3. Sustained/Controlled‐Release Oral Drug Delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20080328 Year of fee payment: 15 |
|
EXPY | Expiration of term |